Teladoc Health, Inc. (TDOC) Stock: Price, Forecast & Analyst Target
Teladoc Health, Inc. (TDOC) — MoonshotScore 16/100 (Weak band), calculated Nov 18, 2026. Price $7.79 (-3.35%), as of the Nov 19, 2026 trading session; market cap $1.42B.
Educational signal · not a buy or sell recommendation · How to read this
Teladoc Health, Inc. · TDOC · NYSE
Teladoc Health, Inc. is a global leader in virtual healthcare, providing a range of services and solutions for various medical conditions. The company operates in the United States and internationally, serving employers, health plans, and individual members through its telehealth platform.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Teladoc Health (TDOC)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Cheap; Growth Durability: Growing; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- Altman Z -7.09 · Piotroski F 4
- ROE -11.5% · ROA -2.9% · current ratio 0.87
Holding back: balance-sheet strain
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 16 | Weak | |
| 16 | Weak | |
| 16 | Weak | |
| 16 | Weak | |
| 16 | Weak | |
| 16 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $7.79 | |
| Change on the day | -3.35% | |
| 52-week range | $4.40 – $9.89 | |
| Market capitalisation | $1.42B | — |
| Shares traded on the day | 4.62M |
Price & events
Other perspectives
Council score for Teladoc Health (TDOC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Teladoc Health (TDOC), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Teladoc Health, Inc. (TDOC) is listed on NYSE. It employs 5,124 people and is led by Charles Divita. The market values it at $1.42B.
What do the latest results show for Teladoc Health (TDOC)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $626M | -$50M | -$0.28 (diluted) |
| Q4 FY2025 | $642M | -$25M | -$0.14 (diluted) |
| Q1 FY2026 | $614M | -$64M | -$0.36 (diluted) |
| Q2 FY2026 | $607M | -$39M | -$0.21 (diluted) |
What are the financial strengths and risks for Teladoc Health (TDOC)?
Short answer
The MoonshotScore pillars rate business quality, an attractive price, durable growth, positive momentum as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z -7.09 · Piotroski F 4. Trailing ratios: ROE -11.5% · ROA -2.9% · current ratio 0.87.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -7.09 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-11.5%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Teladoc Health (TDOC)?
Short answer · as of
Current published price targets run low $7.50 · high $11.00 · consensus $9.30 · median $9.00 against a quoted price of $7.79 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Teladoc Health compare with its peers?
Short answer
Teladoc Health's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $35.45 Nov 19, 2026 | $2.61B | 95 5-pillar Nov 18, 2026 | |
| $162.10 Nov 19, 2026 | $1.11B | 92 5-pillar Nov 18, 2026 | |
| $33.18 Nov 19, 2026 | $1.53B | 85 5-pillar Nov 18, 2026 | |
| $26.24 Nov 19, 2026 | $803M | 85 5-pillar Nov 18, 2026 | |
| $24.69 Nov 19, 2026 | $3.15B | 79 5-pillar Nov 18, 2026 | |
| $24.99 Nov 19, 2026 | $530M | 76 5-pillar Nov 18, 2026 | |
| $11.87 Nov 19, 2026 | $737M | 74 5-pillar Nov 18, 2026 | |
| $13.17 Nov 18, 2026 | $817M | 43 5-pillar Nov 18, 2026 | |
| $3.02 Nov 19, 2026 | $1.03B | 42 5-pillar Nov 18, 2026 | |
| $10.68 Nov 19, 2026 | $1.63B | 37 5-pillar Nov 18, 2026 | |
| $45.89 Nov 18, 2026 | $4.03B | 35 5-pillar Nov 18, 2026 | |
| $27.20 Nov 18, 2026 | $2.04B | 32 5-pillar Nov 18, 2026 | |
| Teladoc Health (TDOC) — this page | $7.79 | $1.42B | 16 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $7.50 – $11.00
- Consensus target
- $9.30
- Median target
- $9.00
Consensus record · Captured .
Measured against a quoted price of $7.79 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026
- Transactions
- 60
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 16
- Other transactions
- 44
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held TDOC in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported TDOC in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Teladoc Health (TDOC)?
- Truist Adjusts Teladoc Health Price Target to $9
- Truist Adjusts Price Target on Teladoc Health to $9 From $8, Maintains Hold Rating
- Digital Therapeutics Market Report 2026 | Capitalize on AI-Driven Care as Market Reaches $38.19 Billion by 2030; Omada Health, WellDoc, Teladoc Health and Biofourmis Accelerate
- Virtual Clinics Market Global Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 13% CAGR as Optum, Cigna, Teladoc Health, and Philips Scale AI-Driven Hybrid Care
Investor Questions: TDOC Stock
These answers are editorial: 1 of these 9 answers is drawn from the TDOC research dossier (written May 7, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for TDOC?
TDOC carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is TDOC a good stock to buy?
Stock Expert AI does not rate TDOC buy, sell or hold. Teladoc Health, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the TDOC stock price today?
The last price recorded for Teladoc Health, Inc. (TDOC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the TDOC price target?
The analyst consensus price target for Teladoc Health, Inc. (TDOC), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What does Teladoc Health, Inc. do?
Teladoc Health, Inc. operates as a virtual healthcare provider, offering a comprehensive suite of services that connect patients with doctors, therapists, and other healthcare professionals remotely.
What are the key factors to evaluate for TDOC?
Teladoc Health, Inc. (TDOC) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. The company serves a diverse range of clients, including employers, health plans, and individual members, providing a stable revenue base. Not financial advice.
How frequently does TDOC data refresh on this page?
TDOC's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven TDOC's recent stock price performance?
Teladoc Health, Inc. (TDOC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brand recognition in the telehealth market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TDOC overvalued or undervalued right now?
Teladoc Health, Inc. (TDOC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 7, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com